Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Follow-Up Questions
Who is the CEO of Vaxart Inc?
Mr. Steven Lo is the President of Vaxart Inc, joining the firm since 2024.
What is the price performance of VXRT stock?
The current price of VXRT is $0.3346, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Vaxart Inc?
Vaxart Inc belongs to Biotechnology industry and the sector is Health Care
What is Vaxart Inc market cap?
Vaxart Inc's current market cap is $76.5M
Is Vaxart Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Vaxart Inc, including 4 strong buy, 4 buy, 1 hold, 0 sell, and 4 strong sell
